Therapeutic Options for Disabling Acute Ischemic Stroke

Area of Science:

• Neurology
• Vascular Medicine
• Emergency Medicine

Background:

• Ischemic stroke is a leading cause of disability in the US, affecting up to 3% of the population.
• Effective and timely treatment is crucial for improving patient outcomes and reducing long-term disability.

Purpose of the Study:

• To review the evidence supporting intravenous thrombolytic therapy, including tenecteplase, for acute ischemic stroke.
• To discuss the extended use of thrombectomy for up to 24 hours in select stroke patients.
• To highlight treatment options for patients with large ischemic cores and acute basilar artery occlusions.

Main Methods:

• Literature review of studies on intravenous thrombolysis and mechanical thrombectomy for acute ischemic stroke.
• Analysis of clinical guidelines and trial data.
• Inclusion of a clinical case illustrating thrombectomy in a patient with a large ischemic core.

Main Results:

• Intravenous thrombolytic therapy, including tenecteplase, is supported by strong evidence for acute ischemic stroke.
• Mechanical thrombectomy is effective for up to 24 hours in patients with large ischemic cores and acute basilar artery occlusions.
• The clinical case demonstrates successful thrombectomy in a patient with a large ischemic core.

Conclusions:

• Tenecteplase and thrombectomy represent significant advancements in acute ischemic stroke management.
• Extended treatment windows up to 24 hours are beneficial for select patients, including those with large ischemic cores and basilar artery occlusions.
• These therapies offer hope for reducing disability and improving functional recovery in stroke survivors.